Penumbra Inc

Financials

Flusso di cassa derivante dalle attività operative -33.24 M9.5 M-55.66 M97.33 M168.48 M238.66 M 238.66 M Flussi di cassa derivanti dalle attività di investimento -104.15 M-21.73 M54.79 M-16.08 M77.62 M-404.59 M -404.59 M Liquidità derivante dalle attività di finanziamento 134.92 M836 K11.62 M16.2 M-87.01 M26.53 M 26.53 M Liquidità libera -58 M-11.68 M-74.96 M82.12 M147.3 M174.93 M 174.93 M

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm. In January 2026, Boston Scientific announced it would acquire Penumbra in a $15 billion cash and stock deal. The deal was expected to close by yearend.

PEN

Financials

Penumbra Inc

Notizie

Lo studio Penumbra mostra risultati migliorati per l’embolia polmonare

3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)

Harpreet Grewal, direttore di Penumbra, vende azioni per 32.822$

Penumbra (PEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates

UBS conferma il rating su Penumbra grazie alla fiducia nella trombectomia

UBS reiterates Penumbra stock rating on thrombectomy confidence

Fewer Deals, Bigger Stakes: Deciphering The 2026 M&A Landscape And The Rise Of Megadeals

PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise

UBS conferma rating Neutral su Penumbra, target a $374

UBS reiterates Neutral on Penumbra stock, keeps $374 target